

3800 Reservoir Road, NW Washington, D.C. 20057 **GUMC.Georgetown.edu**

Clinical Research Operations Office (CROO) Clinicaltrials.georgetown.edu

Institutional Research Fee Schedule

Effective February 1, 2025

Institutional Review Board Fees (Non-Negotiable)

The Georgetown University Institutional Review Board (IRB) charges for the review of human subject research funded by private sponsors (predominantly pharmaceutical or device manufacturing companies)

(For more information, visit: https://researchservices.georgetown.edu/irb-fees/)

Institutional Review Board Review of Industry Funded Research*		
Review Level	Review Type	Fee
Full Board	New Protocol Submission	\$3,000.00
Full Board	Continuing Review	\$1,500.00
Full Board	Amendment	\$1,000.00
Expedited Review	New Protocol Submission	\$2,500.00
Expedited Review	Continuing Review	\$500.00
Expedited Review	Amendment*	\$500.00
Exempt Review	New Protocol Submission	\$1,000.00
Expedited Review	Closure Fee	\$350.00

^{* -} IRB fees will not be applied to administrative changes such as staff changes or IRB required administrative updates.

IRB Administrative Review of Industry Funded External IRB Submissions*		
Review Level	Review Type	Fee
Administrative	Initial Review	\$2,000.00
Administrative	Annual Administrative Fee**	\$1,500.00
Administrative	Close Out	\$350.00
Administrative	For Cause Audit	\$1,000.00

GU IRBs are required to conduct substantive and meaningful continuing review of research at intervals appropriate to the degree of risk, but not less than once per year.

Start-Up Fees¹ (Non-Negotiable)

Unless otherwise noted, the amounts listed are direct and will incur an additional 35% overhead.

	Direct:	\$10,000.00
	Indirect:	\$3,500.00
Administrative Start-Up	Total:	\$13,500.00
The Administrative Start-Up Fee is inclusive of the following: completion of feasibility questionnaires, site evaluation/ pre-site selection visits, Departmental and administrative reviews, completion of internal committee applications, protocol specific trainings, protocol implementations, EDC, IVRS (etc), and the creation of the study in Oncore CTMS as well as other Hospital-wide systems		
	Direct:	\$6,100.00
	Indirect:	N/A
Financial Analysis*	Total:	\$6,100.00
The Financial Analysis includes the Creation of the study account, a thorough billing compliance review and Medicare Coverage Analysis, a Hospital compliance review, and an Advarra CTMS Calendar Build fee.		
	Direct:	\$1,500.00
Initial Scientific Review Committee	Indirect:	\$525.00
(Oncology Only)	Total:	\$2,025.00
The Scientific Review Committee conducts a multi-modality Scientific and Feasibility Project Review of new studies with all departments and staff, acts as the DSMB/C for IIT trials, and serves as initial study training for investigators and support staff.		
	Direct:	\$2,500.00
	Indirect:	\$875.00
Regulatory Prep of Initial IRB Submission	Total:	\$3,375.00
For the time and effort of the regulatory team for the following responsibilities: creation and provision of initial regulatory documents, including informed consent form, investigator CV, licensure, FDFs, and other study-related material, and the creation and submission of the initial IRB application.		
	Direct:	\$1,500.00
	Indirect:	\$525.00
Radiology Start-Up	Total:	\$2,025.00
For the time and effort of the radiology department for th	e following responsibilities: Review of	the imaging

For the time and effort of the radiology department for the following responsibilities: Review of the imaging manual, completion of study-specific training on image capture and central radiology processing vendor (if applicable), site initiation visit between radiology personnel and sponsor/CRO, and completion + submission of phantom and qualification scans.

	Direct:	\$3,500.00
	Indirect:	N/A
Pharmacy Start-Up*: Industry sponsored studies	Total:	\$3,500.00
	Direct:	\$1,500.00
Pharmacy Start-Up*: Government sponsored studies	Indirect:	N/A
(cooperatives ECOG etc)	Total:	\$1,500.00
	Direct:	\$1,000.00
	Indirect:	N/A
Pharmacy Start-Up*: Investigator Initiated Studies	Total:	\$1,000.00
For the time and effort of the pharmacy department for the following responsibilities: review protocol, Protocol-specific training for storage, accountability, randomization, inventory and sponsor accountability set-up.		
	Direct:	\$2,500.00
CRU Start-Up / Initiation	Indirect:	\$875.00
(Non-Oncology only, When Applicable)	Total:	\$3,375.00
If the CRU is to be utilized, the start-up fee includes the following: CRU budget development, review of protocol feasibility for the CRU, Coordination of safety, and resource review for SEPCOM, Initiation meeting with PI and study team, Data entry training and other start-up procedures.		
	Direct:	\$3,400.00
	Indirect:	\$1,190.00
CTMF Start-Up	Total:	\$4,590.00
If the CTMF is to be utilized, the start-up fee includes the following: Review and app	roval of all cli	nical trial-

If the CTMF is to be utilized, the start-up fee includes the following: Review and approval of all clinical trial-related documents, Site initiation visits and preparation, site SOP development, Protocol-specific site staff training, and other start-up activities.

1 - All applicable Start-Up fees are non-negotiable for interventional studies. All start-up fees, regardless of study type, must be paid at contract execution, if not earlier. If the contract is not executed, all applicable start-up fees must be paid.

Annual Administrative and Pass-Through Fees

The amounts listed are direct and will incur an additional 35% overhead unless otherwise noted.

	Direct:	\$2,500.00
Regulatory and Administrative	Indirect:	\$875.00
Maintenance	Total:	\$3,375.00
For the time and effort of the regulatory team for the following responsibilities: Maintenance of regulatory documents including updating CVs and licensure, correspondence, and amendments, Preparation of documents and reports for annual IRB Continuing Review, Amendment training for all research staff, Updating all applicable study logs		
	Direct:	\$1,300.00
Annual Scientific Committee Review	Indirect:	\$455.00
(Oncology Only)	Total:	\$1,755.00
For the time and effort of the scientific review committee SAEs, and IND Safety Reports, and review and approve feasibility	•	_
	Direct:	\$1,000.00
	Indirect:	\$350.00
Continuing Review Processing	Total:	\$1,350.00
For the time and effort of the regulatory team to prep the and local IRB	continuing review application for inter-	nal committees
	Direct:	\$800.00
	Indirect:	\$280.00
Amendment Processing	Total:	\$1,080.00
For the time and effort of the regulatory team to prep the amendment application for internal committees and local IRB		
	Direct:	\$2,400.00
	Indirect:	N/A
Pharmacy Maintenance*	Total:	\$2,400.00
Pharmacy maintenance is calculated at a \$200 per month rate which is \$2400 annually. For the time and effort of the pharmacy staff for the following responsibilities: Receipt of IP and acknowledgment temperature monitoring device (if applicable), Drug accountability and maintenance of regulatory documents, Storage of IP/storage of		

returned IP, Procuring of commercial drugs reimbursed by the sponsor

Direct:	\$75.00	
Indirect:	\$26.25	
Total:	\$101.25	
get and non-target lesions, and evaluation	on of overall	
Direct:	\$75.00	
Indirect:	\$26.25	
Total:	\$101.25	
fer to the central radiology processing v	endor	
Direct:	\$100.00	
Indirect:	\$35.00	
Total:	\$135.00	
follow-up report including EDC and other required forms, file SAE reports to internal committees and local/central IRB Direct: \$50.00		
Indirect:	\$17.50	
Total:	\$67.50	
orts for internal committee and local/cer	ntral IRB review,	
Direct:	\$150.00	
Indirect:	\$52.50	
Total:	\$202.50	
=	quires a second	
Direct:		
	\$150.00	
Indirect:	\$150.00 \$52.50	
Indirect: Total:	·	
	Indirect: Total: get and non-target lesions, and evaluation Direct: Indirect: Total: fer to the central radiology processing volume and local/cents for internal committee and local/cents. Direct: Indirect:	

	Fresh (Direct):	\$300.00
	Fresh (Indirect):	\$105.00
	Fresh (Total):	\$405.00
	Archive (Direct):	\$450.00
	Archive (Indirect):	\$157.50
Processing of Biopsy Tumor Samples	Archive (Total):	\$607.50
For time and effort of study team to re-consent subjects a	s a result of sponsor-initiated protocol	amendment
	Direct:	\$75.00
Processing of Central Lab Sample (per	Indirect:	\$26.25
sample)	Total:	\$101.25
For the time and effort of the study team to re-consent su	-	rotocol
amendment, and generally included in the per-patient buc		* 400 00
	Onsite (Direct):	
	Onsite (Indirect):	\$140.00
	Onsite (Total):	\$540.00
	Remote (Direct):	\$200.00
	Remote (Indirect):	\$70.00
Monitoring Visits (per day)	Remote (Total):	\$270.00
This fee is incurred during sponsor monitoring visits and availability to allow direct access to the EMR system, dat regulatory staff availability for regulatory document review.	a manager availability for data/query r	
	Direct:	\$1,000.00
	Indirect:	\$350.00
Not-For-Cause Audit	Total:	\$1,350.00
For time and effort of study team to prep, host, and review	w a not-for-cause audit	
	Direct:	\$5,000.00
	Indirect:	\$1,750.00
Advertisement (per study)	Total:	\$6,750.00
The sponsor and IRB must approve the text of any comm newspaper/radio advertisements, direct mail pieces, international communications and the sponsor and the	• • • • • • • • • • • • • • • • • • • •	
		Direct
Informed Consent Transl		Invoice
When utilizing a 3rd party for ICF translations, we are su costs onto the sponsor when necessary.	bject to their fee schedules and therefor	re pass those
1 - ··		

Additional Pharmacy Fees

The amounts listed are direct and will incur an additional 35% overhead unless otherwise noted.

	Oral (PO), Topical, Inh, Inj Simple (Direct):	\$50.00
	Oral (PO), Topical, Inh, Inj Simple (Indirect):	\$17.50
	Oral (PO), Topical, Inh, Inj Simple (Total):	\$67.50
	Oral (PO), Topical, Inh, Inj Moderate (Direct):	\$75.00
	Oral (PO), Topical, Inh, Inj Moderate (Indirect):	\$26.25
	Oral (PO), Topical, Inh, Inj Moderate (Total):	\$101.25
Pharmacy Dispensing	Oral (PO), Topical, Inh, Inj Complex (Direct):	\$100.00
	Oral (PO), Topical, Inh, Inj Complex (Indirect):	\$35.00
	Oral (PO), Topical, Inh, Inj Complex (Total):	\$135.00
	IV, Simple (Direct):	\$80.00
	IV, Simple (Indirect):	\$28.00
	IV, Simple (Total):	\$108.00
	IV, Moderate (Direct):	\$125.00
	IV, Moderate (Indirect): IV, Moderate (Total):	
	IV, Complex (Direct):	\$200.00
	IV, Complex (Indirect):	\$70.00
	IV, Complex (Total):	\$270.00
TT1: 0 : 1.1 1:	1 1 1 0.1 1 0.1 TD 1	

This fee is assessed depending upon the complexity of the preparation process of the IP, per dispensation and generally included in the per patient budget.

	Storage at Room Temperature, Direct:	\$125.00
	Storage at Room	·
	Temperature, (Indirect):	N/A
	Storage at Room Temperature, (Total):	\$125.00
	Storage at Non-Room Temperature, Direct:	\$150.00
	Storage at Non-Room Temperature, (Indirect):	N/A
Inventory Management (per month)	Storage at Non-Room Temperature, (Total):	\$150.00
	Direct:	\$500.00
	Indirect:	N/A
Pharmacy: After-Hour Fees (per event)	Total:	\$500.00
	Direct:	\$500.00
Pharmacy: Keeping Patient Returns (per	Indirect:	N/A
year)	Total:	\$500.00
	Direct:	\$500.00
Pharmacy: Saving Opened or Empty Vials	Indirect:	N/A
(per year)	Total:	\$500.00
	Direct:	\$125.00
Pharmacy: Send Study Monthly Temp Log	Indirect:	N/A
(per event)	Total:	\$125.00
	Direct:	\$50.00
Pharmacy: Pharmacy Randomization (each	Indirect:	N/A
subject)	Total:	\$50.00
	Direct:	\$50.00
Pharmacy: Shipping Fee (Supplier to	Indirect:	N/A
Center, Center to Center)	Total:	\$50.00

	Direct:	\$50.00
Pharmacy: Re-labeling of New Expiration Date - Simple (up to 2 bottles per dispense)	Indirect:	N/A
	Total:	\$50.00
	Direct:	\$100.00
Pharmacy: Re-labeling of New Expiration Date - Complex (> 2 bottles per dispense)	Indirect:	N/A
	Total:	\$100.00
Pharmacy: Commercial Drug Markup for Sponsor Reimbursed Commercial Supply (WAC cost plus markup)	Direct:	\$200.00
	Indirect:	N/A
	Total:	\$200.00

Pharmacy Fees cover, but are not limited to, the cost associated with the oncology research pharmacist's time and expertise and the facility requirements for the investigational products. Simple or complex assignments are made based on the intricacy of the project and/or the number of study investigational products.

- Pharmacy start-up fees include costs associated with the research pharmacist's review, planning, and set-up of the project

Pharmacy Maintenance fees (paid monthly or quarterly) include receipt, inventory, and documentation of investigational products and a fee for physical space used to store the study drugs. The fee will continue to accrue on at least a monthly basis until the sponsors retrieve the investigational product and any/all associated study materials from the MedStar Research Pharmacy.

- Pharmacy close-out fee includes costs associated with the research pharmacist's time to effect close-out of study investigational products, archiving, and storing the research pharmacy record.
- MedStar Research Pharmacy will review and update this document **every 2 years** to reflect the current marketing situation

Closeout Fees

The amounts listed are direct and will incur an additional 35% overhead unless otherwise noted.

	Direct:	\$2,500.00
	Indirect:	\$875.00
Study Close-Out	Total:	\$3,375.00
For time and effort of study team to resolve of all regulat applicable logs, and all essential regulatory documents, C storage and/or return to sponsor, prep study files for long	Collect all study-related materials and ed	
	Direct:	\$500.00
	Indirect:	N/A
Pharmacy* Closeout	Total:	\$500.00
For time and effort of the pharmacy team for destruction, the study close-out visit.	return of IP, close-out IP inventory, and	d participate in
	Direct:	\$2,500.00
	Indirect:	\$875.00
Archiving and Document Storage	Total:	\$3,375.00
For the time and effort of the study team to transfer study fees for the time frame required by the sponsor	y files to a storage facility, and for the n	nonthly storage
	Direct:	\$1,500.00
CRU Close-Out	Indirect:	\$525.00
(Non-Oncology only, When Applicable)	Total:	\$2,025.00
Includes all study closure activities and necessary steps to study	o ensure all aspects are addressed prior	to closing the
* - Direct Cost Only; no applicable Overhead		
Suhail Qureshi, MD (FMG), MHA	04/17/2025	
Suhail Qureshi, Director, Clinical Research Operations Office Georgetown University Medical Center	Date	